[go: up one dir, main page]

BR0013281A - Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais - Google Patents

Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais

Info

Publication number
BR0013281A
BR0013281A BR0013281-0A BR0013281A BR0013281A BR 0013281 A BR0013281 A BR 0013281A BR 0013281 A BR0013281 A BR 0013281A BR 0013281 A BR0013281 A BR 0013281A
Authority
BR
Brazil
Prior art keywords
preparation
arylmethyl
carbonylamino
thiazole derivatives
antitumor agents
Prior art date
Application number
BR0013281-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Paolo Pevarello
Raffaella Amici
Mario Varasi
Manuela Villa
Anna Vulpetti
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0013281A publication Critical patent/BR0013281A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BR0013281-0A 1999-08-12 2000-08-11 Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais BR0013281A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/372,832 US6114365A (en) 1999-08-12 1999-08-12 Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
PCT/IB2000/001423 WO2001014353A1 (fr) 1999-08-12 2000-08-11 Derives d'arylmethyl-carbonylamino-thiazole utilisation de ceux-ci comme agents antitumoraux

Publications (1)

Publication Number Publication Date
BR0013281A true BR0013281A (pt) 2002-06-18

Family

ID=23469806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013281-0A BR0013281A (pt) 1999-08-12 2000-08-11 Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais

Country Status (36)

Country Link
US (3) US6114365A (fr)
EP (1) EP1204649B1 (fr)
JP (1) JP4864260B2 (fr)
KR (2) KR100773709B1 (fr)
CN (1) CN100410245C (fr)
AP (1) AP1853A (fr)
AT (1) ATE375987T1 (fr)
AU (1) AU782882B2 (fr)
BG (1) BG65484B1 (fr)
BR (1) BR0013281A (fr)
CA (1) CA2381097C (fr)
CY (1) CY1107108T1 (fr)
CZ (1) CZ303138B6 (fr)
DE (1) DE60036803T2 (fr)
DK (1) DK1204649T3 (fr)
EA (1) EA005375B1 (fr)
EE (1) EE04939B1 (fr)
ES (1) ES2295056T3 (fr)
GE (1) GEP20053475B (fr)
HK (1) HK1054233B (fr)
HR (1) HRP20020127B1 (fr)
HU (1) HUP0202492A3 (fr)
IL (2) IL147924A0 (fr)
IS (1) IS2594B (fr)
MA (1) MA25433A1 (fr)
MX (1) MXPA02001508A (fr)
NO (1) NO323576B1 (fr)
NZ (1) NZ517236A (fr)
OA (1) OA12047A (fr)
PT (1) PT1204649E (fr)
RS (1) RS50300B (fr)
SI (1) SI1204649T1 (fr)
SK (1) SK287373B6 (fr)
UA (1) UA72538C2 (fr)
WO (1) WO2001014353A1 (fr)
ZA (1) ZA200201117B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
CN101481359A (zh) 1999-04-15 2009-07-15 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20040048844A1 (en) * 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
CA2430151A1 (fr) * 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Derives phenylacetamido-pyrazole et leur utilisation comme agents antitumoraux
WO2002044174A2 (fr) * 2000-12-01 2002-06-06 Bristol-Myers Squibb Pharma Company Derives de 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one et leur utilisation
CA2430376A1 (fr) 2000-12-08 2002-06-13 David J. Carini Semi-carbazides et leurs utilisations en tant qu'inhibiteurs de kinases dependantes des cyclines
AU3113902A (en) * 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
GEP20105095B (en) * 2001-07-19 2010-10-25 Pfizer Italia Srl Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
EP1724270A3 (fr) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Dérivés de phenylacetamido-thiazole, leur procédé de préparation et leur utilisation en tant qu'agents antitumoraux
EP1436286B1 (fr) * 2001-09-27 2009-08-19 Equispharm Co., Ltd. Derives de fumagillol et procede permettant de les preparer
EP1458382A1 (fr) * 2001-12-21 2004-09-22 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
WO2004002481A1 (fr) * 2002-06-27 2004-01-08 Novo Nordisk A/S Activateurs de la glycokinase
JP2006517577A (ja) * 2003-02-12 2006-07-27 ファイザー・インク 抗増殖性の2−(スルホ−フェニル)−アミノチアゾール誘導体
MXPA05008878A (es) * 2003-02-21 2005-10-05 Pfizer Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
CA2520957C (fr) * 2003-03-31 2013-08-06 Sucampo Ag Procede de traitement de maladie vasculaire hyperpermeable
WO2005014591A1 (fr) * 2003-07-15 2005-02-17 L'oreal 2-acylamino ou 2-sulfonylamino-1, 3-thiazoles en tant qu'agents de couplage pour la coloration d'oxydation de fibres keratiniques
FR2857664B1 (fr) * 2003-07-15 2007-12-14 Oreal Nouveaux derives thiazoles et utilisation de ces derives pour la teinture des fibres keratiniques
US7351727B2 (en) * 2003-09-02 2008-04-01 Bristol-Myers Squibb Company Inhibitors of 15-lipoxygenase
US20050074424A1 (en) * 2003-10-03 2005-04-07 Lev Salnikov Using polyion polymers with glucose infusion for a cancer selective chemotherapy compound and method
US20070196395A1 (en) * 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
AU2005203930C1 (en) * 2004-01-06 2012-02-23 Vtv Therapeutics Llc Heteroaryl-ureas and their use as glucokinase activators
WO2006002119A2 (fr) 2004-06-18 2006-01-05 Gpc Biotech, Inc. Utilisation d'inhibiteurs de kinase et leurs compositions
EP1621539A1 (fr) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases
EP1621536A1 (fr) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Dérivés d'urées cycliques aminés, leur préparation et utilisation pharmaceutique en tant qu'inhibiteurs de Kinase
EP2620150A3 (fr) * 2004-08-13 2014-01-08 Genentech, Inc. Inhibiteurs à base de 2-amido thiazole d'enzymes utilisant l'ATP
EP2096107A1 (fr) 2004-12-23 2009-09-02 GPC Biotech AG Dérivés d'acide squarique dotés d'une activité anti-proliférante
CA2618646A1 (fr) * 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
JP2009500378A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー/エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
EP1904467B1 (fr) 2005-07-14 2013-05-01 Novo Nordisk A/S Activateurs de l'urée glucokinase
EP1914234A1 (fr) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
US8138185B2 (en) * 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
AU2008204530B2 (en) * 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
WO2008098949A2 (fr) * 2007-02-13 2008-08-21 Ab Science Procédé de synthèse de composés 2-aminothiazole comme inhibiteurs de kinase
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
TWI437986B (zh) * 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為vap-1抑制劑之用途
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
EP2112152A1 (fr) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones comme inhibiteurs Plk
US8343996B2 (en) 2008-11-13 2013-01-01 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2440556A1 (fr) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de la phosphatidylinositol 3-kinase
DE102009043260A1 (de) * 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
EP2325185A1 (fr) 2009-10-28 2011-05-25 GPC Biotech AG Inhibiteur de Plk
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
US8883793B2 (en) 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
CN103387551B (zh) 2012-05-11 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 噻唑类化合物及其用途
SG11201501041VA (en) 2012-08-23 2015-03-30 Virostatics Srl Novel 4,6-disubstituted aminopyrimidine derivatives
DK3777855T3 (da) 2016-04-11 2023-01-09 Genfit Fremgangsmåder til behandling af fibrotiske sygdomme
KR20200104873A (ko) 2017-12-06 2020-09-04 린 바이오사이언스, 피티와이 엘티디. 튜불린 억제제
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
EP3941900A1 (fr) 2019-03-22 2022-01-26 Deutsches Krebsforschungszentrum Nouveaux inhibiteurs de l'histone désacétylase 10
EP3712127A1 (fr) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Nouveaux inhibiteurs de l'histone déacétylase 10
EP4015506A4 (fr) * 2019-09-25 2023-08-30 Korea Institute of Radiological & Medical Sciences Composition pour prévenir ou traiter le cancer, contenant un dérivé à base de trifluorométhylphényl pyrazole comme principe actif
WO2021162054A1 (fr) * 2020-02-10 2021-08-19 学校法人順天堂 Inhibiteur de l'activité du récepteur de la ryanodine de type 2
CN115322208B (zh) * 2021-05-10 2023-04-11 中国药科大学 2-氨基噻唑类衍生物及其制备方法和医药用途
AU2023239988A1 (en) * 2022-03-22 2024-10-10 Autotelic Bio Inc. Thiazole derivative compound and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125062C (fr) * 1960-04-20
JPH1095777A (ja) * 1996-07-31 1998-04-14 Otsuka Pharmaceut Co Ltd チアゾール誘導体
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
YU22400A (sh) * 1997-10-27 2003-08-29 Agouron Pharmaceuticals Inc. Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JP2002518380A (ja) * 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
CN101481359A (zh) * 1999-04-15 2009-07-15 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6992081B2 (en) * 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
SE0102440D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compound
US6936629B2 (en) * 2001-12-21 2005-08-30 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
JP4650412B2 (ja) * 2003-01-27 2011-03-16 アステラス製薬株式会社 チアゾール誘導体およびvap−1阻害剤としてのその使用

Also Published As

Publication number Publication date
EP1204649B1 (fr) 2007-10-17
CY1107108T1 (el) 2012-10-24
NZ517236A (en) 2004-11-26
NO20020683D0 (no) 2002-02-11
DE60036803T2 (de) 2008-07-24
US6114365A (en) 2000-09-05
KR100827563B1 (ko) 2008-05-07
SI1204649T1 (sl) 2008-02-29
CA2381097A1 (fr) 2001-03-01
OA12047A (en) 2006-05-02
JP2003507461A (ja) 2003-02-25
HUP0202492A2 (hu) 2002-11-28
DK1204649T3 (da) 2007-12-03
AP2002002441A0 (en) 2002-03-31
EE200200064A (et) 2003-04-15
PL353588A1 (en) 2003-12-01
US6784198B1 (en) 2004-08-31
BG106481A (en) 2002-09-30
KR100773709B1 (ko) 2007-11-09
HRP20020127B1 (en) 2010-08-31
AU782882B2 (en) 2005-09-08
US20050004120A1 (en) 2005-01-06
IS2594B (is) 2010-03-15
BG65484B1 (bg) 2008-09-30
WO2001014353A1 (fr) 2001-03-01
SK1802002A3 (en) 2003-05-02
NO20020683L (no) 2002-04-10
EP1204649A1 (fr) 2002-05-15
GEP20053475B (en) 2005-03-25
KR20070074003A (ko) 2007-07-10
CN1425009A (zh) 2003-06-18
HK1054233A1 (en) 2003-11-21
ATE375987T1 (de) 2007-11-15
EA200200247A1 (ru) 2002-08-29
IL147924A (en) 2008-03-20
SK287373B6 (sk) 2010-08-09
EA005375B1 (ru) 2005-02-24
RS50300B (sr) 2009-09-08
YU9702A (sh) 2004-11-25
UA72538C2 (en) 2005-03-15
AU7440000A (en) 2001-03-19
CA2381097C (fr) 2009-06-16
IL147924A0 (en) 2002-08-14
HUP0202492A3 (en) 2004-12-28
DE60036803D1 (de) 2007-11-29
CZ303138B6 (cs) 2012-04-25
JP4864260B2 (ja) 2012-02-01
ES2295056T3 (es) 2008-04-16
KR20020060159A (ko) 2002-07-16
CN100410245C (zh) 2008-08-13
CZ2002486A3 (cs) 2002-11-13
AP1853A (en) 2008-05-29
NO323576B1 (no) 2007-06-11
PT1204649E (pt) 2008-01-10
MXPA02001508A (es) 2003-07-21
EE04939B1 (et) 2007-12-17
ZA200201117B (en) 2003-04-30
HRP20020127A2 (en) 2003-04-30
HK1054233B (zh) 2009-05-29
IS6264A (is) 2002-02-11
MA25433A1 (fr) 2002-04-01

Similar Documents

Publication Publication Date Title
BR0013281A (pt) Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais
BR0013277A (pt) Derivados de 3(5) ureido-pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
BR0013143A (pt) Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
BR0212841A (pt) Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0418184A (pt) derivados de pirrol[2,3-b]piridina ativos como inibidores de quinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
BRPI0414330A (pt) composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
EA199901031A1 (ru) Производные бензимидазола
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.